Read our latest updates & insights

Korea Biomedical Review reported that Samsung Bioepis and Genetech have signed a licence agreement for ranibizumab.  Under the terms of the agreement, Samsung Bioepis can market its biosimilar ranibizumab from June 2022.

PharmGene Science and Access Bio announced that they have signed a Memorandum of Understanding for the joint development and commercialisation of a biosimilar mRNA COVID-19 vaccine.

Business Standard reported that Aurobindo Pharma (through the subsidiary CuraTeQ Biologics) has submitted a Marketing Authorisation Application to the EMA for BP14 (proposed biosimilar pegfilgrastim).

Syneos Health and CuraTeQ Biologics (a subsidiary of Aurobindo) are recruiting participants for a comparative trial to be conducted in New Zealand to assess the pharmacokinetics, pharmacodynamics, safety and immunogenicity of 3 different products (BP11, US-Xolair and EU-Xol...

180 Life Sciences and Celltrion announced that they have entered into a Memorandum of Understanding for the supply of an anti-TNF biosimilar drug to be used for new indications with significant unmet medical needs.

AbbVie announced it has submitted the regulatory application for Skyrizi® (risankizumab) to the FDA for the treatment of patients 16 years and older with moderate to severe Crohn’s Disease.